PT Itama Ranoraya Tbk entered into a conditional share purchase agreement to acquire a 51% stake in PT Oneject Indonesia.
September 30, 2021
Share
PT Itama Ranoraya Tbk (IDX:IRRA) entered into a conditional share purchase agreement to acquire a 51% stake in PT Oneject Indonesia on September 30, 2021. Under the terms, the purchase consideration will be carried out in 2 tranches, an initial payment of approximately IDR 200 billion, which is paid at the signing of the agreement and a final payment of the total agreed acquisition price minus the initial payment. The transaction initial consideration funded from the sale of 100 million treasury shares and the final payment will be funded from the issuance of new shares. After the acquisition, PT Itama will become the majority shareholder of PT Oneject with an ownership portion of 51%. PT Itama will seek approval from shareholders for approval of the PT Oneject acquisition and approval for the issuance of new shares (rights issue) in order to finance the acquisition at the extraordinary General Meeting of shareholders to be held in the first quarter of 2022. The transaction is expected to be completed no later than the first half of 2022.
PT Itama Ranoraya Tbk is an Indonesia-based healthcare company, which is engaged in offering healthcare solutions. The Company operates in the field of wholesale trading of laboratory equipment, pharmaceutical equipment, and medical devices for humans. The Company carries out its operations through four products, namely the non-electromedical sterile medical devices, in-vitro diagnostic, electromedical sterile medical devices, and other products. Its business segment focuses on in-vitro diagnostic (IVD), medical imaging, surgical instrument and disposable, critical care, blood banking and transfusion, cardiovascular, brain management, cancer, urology, and maternal and neonatal care. Its products include Oneject, Abbott, Terumo, Becton Dickinson (BD), HMD, Vestfrost, Balmed, iGene, AVIMAC, and HemoCue.